Abstract

The present disclosure relates to the field of biomedicine, in particular to the use of MCM8-cGAS-STING-IFN-I signal pathway as a disease target, including the use in the preparation of an animal model of a disease or the preparation of a product for the diagnosis, prevention, or treatment of a disease. In particular, the present disclosure comprises the use of a reagent for quantitatively detecting the gene expression or protein expression or protein activity of MCM8 in the preparation of a product for the diagnosis of a disease caused by dysfunctional mitophagy or caused by abnormal activation of cGAS-STING-IFN-I signaling pathway.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided are a miRNA molecule miR-206 for regulating and controlling uterine muscle contraction and use thereof, particularly use of miR-206, a precursor of miR-206, or a miR-206 mimic in preparing a drug for preventing and/or treating premature birth.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 15/06 - Antiabortive agentsLabour repressants
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to the technical field of biomedicine. Disclosed is an application of folic acid in prevention, diagnosis, and treatment of hereditary, infectious, or allergic diseases. It is found in the present invention that folic acid promotes expression of Nox2 by improving inflammation, regulating metabolism of an iron ion, correcting disturbance of intestinal flora, alleviating liver/intestinal tissue damage, and inhibiting expression of an inflammatory factor, to achieve prevention and treatment of hereditary, infectious, or allergic diseases. Meanwhile, the present invention provides an application of one or more of folic acid, S100a8, S100a9, Nox2, and IFN-γ as a diagnostic or auxiliary diagnostic marker for biliary atresia. Meanwhile, provided is folic acid or a derivative thereof which is prepared as food, nutritional preparation, or medicine, is used in children or adults, and achieves the purpose of prevention and treatment of related diseases such as biliary atresia, cholangitis, jaundice, infectious diseases, and bowel diseases and diseases caused by abnormal folic acid metabolism.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/315 - Zinc compounds
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 38/06 - Tripeptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to a fibrotic disease mechanism, and a preventive/therapeutic drug and method therefor. The present invention can improve the level of cAMP by means of a PDE inhibitor such as dipyridamole to treat fibrotic diseases and inhibit the progress of fibrosis. The present invention further achieves anti-inflammatory and immune regulation effects, and achieves a therapeutic effect on all aspects of the occurrence and development of fibrosis.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention provides an application of N-acetylcysteine in the preparation of a product for treating biliary atresia, and a drug for treating biliary atresia, which relate to the technical field of disease treatment. By means of research by inventors, it has been found that after N-acetylcysteine is administered to treat children suffering from biliary atresia, the number of CD177+ neutrophils and cell viability (ROS level, mitochondrial level and extracellular trap level) of the children suffering from biliary atresia are significantly reduced, and direct bilirubin and total bilirubin are markedly reduced. N-acetylcysteine improves the treatment of biliary atresia, the safety of N-acetylcysteine is reliable, and N-acetylcysteine may be used for preparing a product for treating biliary atresia. The drug for treating biliary atresia as provided in the present invention comprises N-acetylcysteine, and treats biliary atresia.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A diagnostic marker combination for Hirschsprung disease, a diagnostic product for Hirschsprung disease, and an application of the combination in the preparation of a diagnostic reagent, kit or test strip for Hirschsprung disease. The diagnostic marker combination for Hirschsprung disease comprises two to five antibodies selected from an anti-NMDAR antibody, an anti-single-stranded DNA antibody, an anti-double-stranded DNA antibody, an anti-SSA antibody, and an anti-nRNP/Sm antibody. The diagnostic product for Hirschsprung disease comprises a detection agent for one to five of an anti-NMDAR antibody, an anti-single-stranded DNA antibody, an anti-double-stranded DNA antibody, an anti-SSA antibody, and an anti-nRNP/Sm antibody.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

Disclosed are a marker for the diagnosis or early diagnosis of Hirschsprung's disease and an application thereof; one or both detection means among PRDM9 transposon fusion and/or CMV are used as markers for Hirschsprung's disease, and an application of a detection agent of the marker(s) in the preparation of reagents, kits or other diagnostic products for Hirschsprung's disease. Compared with traditional diagnostic methods (barium enema, etc.), the present invention has many comprehensive advantages such as earlier diagnosis time, simple and fast operation, no intervention, high throughput, low costs, etc. The present invention effectively makes up for the deficiencies in the existing technology, and is an effective alternative or auxiliary detection method for Hirschsprung's disease diagnosis (especially early diagnosis). Moreover, the present method has good stability, and has good diagnostic results in multiple independent cohorts, filling the gap in the diagnosis or early diagnosis of Hirschsprung's disease.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to gastrointestinal diseases, such as non-infectious gastrointestinal diseases, including the immune mechanism of non-infectious gastrointestinal diseases in children, and the use of phosphodiesterase inhibitors and/or antiplatelet drugs in the treatment of gastrointestinal diseases such as non-infectious gastrointestinal diseases.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

An application of a crotonic acid salt in the preparation of a drug for treating a heart disease. A crotonic acid salt preparation and a method for preparing same. The method is characterized by comprising: mixing a crotonic acid solution with an alkaline substance and adjusting the pH to 6.8-7.4, so as to form a crotonic acid salt preparation.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
• C07C 57/08 - Crotonic acid

Abstract

Disclosed in the present invention is a use of a reagent for inhibiting MHC-I and/or II signal pathways in the treatment of biliary atresia. In the present invention, it is found by means of a model of BA disease induced by Rhesus monkey rotavirus (RRV) that the reagent for inhibiting MHC-I and/or II signaling pathways can significantly reduce the degree of liver injury and inhibit BA disease progression.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A drug and a method for preventing/treating biliary atresia, the method comprising administering a drug for removing B cells to a subject, wherein the drug for removing B cells is selected from a CD20 inhibitor, a B cell maturation antigen inhibitor, and a CD79 inhibitor. The CD20 inhibitor is selected from rituximab, ibritumomab, tositumomab or an analog thereof, and has a certain significance for the clinical treatment of biliary atresia.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to the field of biomedical treatment, and specifically to a use of an MCM8-cGAS-STING-I-type interferon signal pathway as a disease target. The use comprises a use in preparing an animal disease model or preparing a product for diagnosing, preventing, or treating a disease. Specifically, the use of a reagent for quantitatively determining gene expression or protein expression or protein activity of MCM8 in preparing a product for diagnosing a disease is comprised, wherein the disease is a disease caused by abnormal mitophagy or a disease caused by abnormal activation of a cGAS-STING-I-type interferon signal pathway; if the gene expression or protein expression or protein activity of the MCM8 is reduced relative to a reference level, the disease is diagnosed as said disease; and the reference level represents the gene expression level or protein expression level or protein activity level of the MCM8 from the same age group of subjects without the disease.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

22 does not take the difference between the inspiratory volume and the expiratory volume into consideration and is not suitable for use on a patient under mechanical ventilation, resulting in unreliable clinical application.

IPC Classes  ?

• A61M 16/12 - Preparation of respiratory gases or vapours by mixing different gases

Abstract

The present invention relates to a fibrotic disease mechanism, and a preventive/therapeutic drug and method therefor. The present invention can improve the level of cAMP by means of a PDE inhibitor such as dipyridamole to treat fibrotic diseases and inhibit the progress of fibrosis. The present invention further achieves anti-inflammatory and immune regulation effects, and achieves a therapeutic effect on all aspects of the occurrence and development of fibrosis.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are an intein-mediated nano-carrier and an application thereof. The nano-carrier is constructed by the following steps: introducing three tandem proteins, i.e., intN, gb1 and halo, into a C-terminal of an encapsulin protein by using a gene fusion method so as to form a recombinant protein encapsulin-intN-gb1-halo; subjecting 60 recombinant protein monomers to self-assembly so as to obtain nano-particles, exposed intN-gb1-halo thereof being taken as a universal "adapter", and after the adapter is mixed with cargo recombinant proteins gb1-intCand cargo, performing molecular recombination under the assistance of DTT; and subjecting intein to self-excision to form by-products intN-gb1-halo and gb1-intC, and subjecting encapsulin and the cargo to covalent coupling so as to produce a target product encapsulin-cargo. Also provided is a nano preparation capable of simultaneously delivering an antigen and an immunopotentiator, which formed by fusing an N-terminal of ferritin with a C-terminal of a connector gbl-intein to form a recombinant protein gbl-inteinc-ferrtin, performing self-assembly to obtain 24 polymers to form nanoparticles, fusing a C-terminal of an exogenous protein with an N-terminal of the intein to form the recombinant protein, enabling the N-terminal of the intein to specifically recognize and excise the ferritin exposed on the surface of the nanoparticles, and performing covalent cross-linking of the exogenous protein and the ferritin, wherein the exogenous protein is an immunopotentiator, or an antigen, or a combination of the immunopotentiator and the antigen.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

An intein-mediated nanocarrier module platform, a construction method therefor and an application thereof. The nanocarrier module platform co-delivers an immunopotentiator and an antigen on the same nanocarrier, which significantly improves the assisting effect of an adjuvant. The intein-mediated nanocarrier module platform is polymer nanoparticles self-assembled from a recombinant protein gbl-inteinc-X via molecules formed by fusing a protein X with a C-terminus of an adaptor gbl-intein. An N-terminus of the protein X extends to the surface of the nanoparticles.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

A use of dipyridamole in the preparation of a drug for the treatment of gastrointestinal diseases, the gastrointestinal diseases comprising colitis and inflammatory bowel disease, and the patients preferably being children.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system